MetricStream Announces AI-Powered GRC Leadership Series Workshops
MetricStream, the global market leader in integrated risk management (IRM) and governance, risk, and compliance (GRC), announced today the launch of its AI-Powered GRC Leadership Series, an in-person workshop and networking event featuring Michael Rasmussen, renowned GRC Analyst & Pundit at GRC 20/20 Research. To be held across six key cities across Europe and APAC this February and March, this exclusive event is designed to help organizations accelerate their risk and compliance modernization journey through best practices and AI.
The interactive workshops will cover essential topics including:
- Why traditional GRC approaches need to evolve
- Key strategies for advancing on the GRC maturity journey
- Leveraging emerging technologies like AI to enhance risk and compliance efficiency
- Collaborating across business functions to improve GRC adoption
- GRC journey stories from customers
“We are committed to equipping businesses with AI and integrated GRC programs so they can thrive in today’s complex risk and regulatory environment,” said Manu Gopeendran, SVP, Strategy and Marketing, MetricStream. “The AI-Powered GRC Leadership Series is designed to provide actionable takeaways, understand the practical applications of AI, foster meaningful discussions, and create opportunities for networking with industry peers.”
“Organizations in 2025 are faced with a rapidly evolving regulatory landscape, emerging risks, and unprecedented IT & cyber risks. The traditional methods of managing GRC functions are no longer sufficient,” said Michael Rasmussen, GRC Analyst & Pundit at GRC 20/20 Research. “The GRC by Design workshops offer risk, compliance and audit professionals a hands-on opportunity to delve into these challenges, explore best practices, leverage the power of AI, and discuss innovative strategies that empower organizations to achieve greater efficiency and resilience in their risk and compliance programs.”
This complimentary event series is a must-attend for GRC, risk, compliance, and audit leaders who want to:
- Gain actionable insights into modernizing GRC processes
- Explore the role of AI and technology in transforming risk management
- Network with industry experts and peers in an engaging setting
Attendees will benefit from an immersive session followed by networking, drinks, and hors d’oeuvres.
For more information about the Leadership Series and to reserve your spot, visit the event pages for Singapore, Kuala Lumpur, Manila, Amsterdam, Frankfurt, and Zurich.
MetricStream is the global SaaS leader of Integrated Risk Management and GRC solutions that empower organizations to thrive on risk by accelerating growth via risk-aware decisions. We connect governance, risk management, and compliance across the extended enterprise. Our ConnectedGRC and three product lines – BusinessGRC, CyberGRC, and ESGRC – are based on a single, scalable platform that supports you wherever you are on your GRC journey.
MetricStream is headquartered in San Jose, California, with an operations and R&D center in Bangalore, India, and sales and operations support around the globe. More information is available at www.metricstream.com, and LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250129936835/en/
Contacts
Media Contact:
Patricia A. McParland
Associate Vice President, Marketing
pr@metricstream.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Coincheck Group N.V. to Announce Third Quarter 2025 Results on February 12, 202531.1.2025 15:30:00 EET | Press release
Coincheck Group N.V. (the “Company”) (Nasdaq: CNCK), the holding company for Coincheck, Inc, a leading Japanese crypto exchange, today announced that the Company will release its third quarter 2025 financial results on Wednesday, February 12, 2025. The Company will host a conference call to discuss third quarter 2025 financial results at 5:00 pm ET that same day. Hosting the call will be Oki Matsumoto, Executive Chairman, Gary Simanson, Chief Executive Officer, and Jason Sandberg, Chief Financial Officer. The call will be webcast live from the Company's website at www.coincheckgroup.com. A replay will be available on the Company’s investor relations website following the call. The conference call can also be accessed over the phone by dialing (877) 407-4018 or (201) 689-8471; the Conference ID is 13751285. About Coincheck Group N.V. Headquartered in the Netherlands, Coincheck Group N.V. (NASDAQ: CNCK) is a public limited liability company and the holding company for Coincheck, Inc. Coi
Datopotamab Deruxtecan Recommended for Approval in the EU by CHMP for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast Cancer31.1.2025 15:00:00 EET | Press release
Datopotamab deruxtecan (Dato-DXd) has been recommended for approval in the European Union (EU) for the treatment of adult patients with unresectable or metastatic hormone receptor (HR) positive, HER2 negative (IHC 0, IHC 1+ or IHC 2+/ISH-) breast cancer who have received endocrine therapy and at least one line of chemotherapy in the advanced setting. Datopotamab deruxtecan is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE:45680) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/Nasdaq: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast01 phase 3 trial published in the Journal of Clinical Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast01, datopot
REPLY: Coding and Cybersecurity, Registration Is Now Open for the Reply Hack The Code Challenge 202531.1.2025 13:42:00 EET | Press release
Reply has announced the opening of registrations for the ReplyHackThe Code Challenge 2025, the leading online team coding competition, which will take place on March 12th 2025. This year's challenge will combine programming and cybersecurity for the first time, offering participants the opportunity to tackle algorithmic problems and cybersecurity challenges. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250131992792/en/ Reply has announced the opening of registrations for the Reply Hack The Code Challenge 2025, the leading online team coding competition, which will take place on March 12th 2025. This year's challenge will combine programming and cybersecurity for the first time, offering participants the opportunity to tackle algorithmic problems and cybersecurity challenges. (Photo: Business Wire) The competition follows the format of previous events, with two parallel challenges: the Standard Edition, aimed at university
GE HealthCare Invests $138 Million in Cork, Ireland Manufacturing Facility to Address Increasing Contrast Media Demand31.1.2025 10:00:00 EET | Press release
GE HealthCare (Nasdaq: GEHC) today announced a $138 million investment to expand its Carrigtohill, Cork contrast media fill and finish manufacturing site in Ireland. A new state-of-the-art facility on the grounds of the existing site will enable 25 million more patient doses per year of contrast media by the end of 2027, helping address growing global demand. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250130241464/en/ GE HealthCare’s contrast media manufacturing site in Cork (Photo: Business Wire) Contrast media are injectable diagnostic imaging agents used to enhance visualization of organs, blood vessels and tissues during medical imaging. Global demand for iodine-based contrast media, used in X-Ray, Computed Tomography (CT) and Interventional procedures is expected to double in the next decade, driven by ageing populations and the increasing global prevalence of chronic disorders. In 2024, the Carrigtohill facility, a
Vertex Announces CASGEVY ® Reimbursement Agreement for the Treatment of Sickle Cell Disease in England31.1.2025 09:00:00 EET | Press release
Vertex Pharmaceuticals (Nasdaq: VRTX) announced today a reimbursement agreement with NHS England for eligible sickle cell disease (SCD) patients to access the CRISPR/Cas9 gene-edited therapy, CASGEVY® (exagamglogene autotemcel). The reimbursement agreement comes as the National Institute for Health and Care Excellence (NICE) issues positive guidance recommending CASGEVY’s use in the NHS. It means that eligible SCD patients in England now have access to the therapy following the prior agreement for transfusion-dependent beta thalassemia (TDT) patients announced last August. “Today is an important day for the sickle cell community who have gone too long without treatments that address the underlying cause of their devastating disease,” said Ludovic Fenaux, Senior Vice President, Vertex International. “We are pleased to have reached this new agreement that ensures both eligible SCD and TDT patients can now be treated with CASGEVY, recognizing the value a one-time treatment can provide to
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom